Addario Lung Cancer Medical Institute:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Addario Lung Cancer Medical Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9295
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Addario Lung Cancer Medical Institute (ALCMI) is a non-profit organization that concentrates on scientific and clinical research and diagnostics for lung cancer. The organization involves in research advancements, invests in discovery of improved treatments and also facilitates early detection, diagnostics, and others. It has established tumor, blood, urine biobanks, data banks and study management systems which contribute for the lung cancer research consortium with various member institutions to discover and develop treatment and diagnosis for lung cancer. ALCMI works on various projects such as small cell lung cancer, young lung cancer and also indentifies the genetic mutations, among others. The organization works in partnership with Bonnie J Addario Lung Cancer Foundation. ALCMI is headquartered in San Carlos, California, the US.

Addario Lung Cancer Medical Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Addario Lung Cancer Medical Institute, Medical Devices Deals, 2012 to YTD 2018 9
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Champions Oncology Enters into Agreement with Addario 11
Addario Lung Cancer Medical Institute, Champions Oncology and ROS1ders Enter into Agreement 12
Addario Lung Cancer Medical Institute Enters into Agreement with Scancell 13
Addario Lung Cancer Medical Institute – Key Competitors 14
Addario Lung Cancer Medical Institute – Key Employees 15
Addario Lung Cancer Medical Institute – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Government and Public Interest 17
May 31, 2018: Bonnie J. Addario Lung Cancer Foundation and Van Auken Private Foundation Announce the 2018 Young Innovators Team Award for Lung Cancer Research 17
Other Significant Developments 18
Feb 21, 2018: Motivated Patients with ROS1 Cancer Initiate Global Research Study 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Key Facts 2
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Addario Lung Cancer Medical Institute, Deals By Therapy Area, 2012 to YTD 2018 8
Addario Lung Cancer Medical Institute, Medical Devices Deals, 2012 to YTD 2018 9
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Champions Oncology Enters into Agreement with Addario 11
Addario Lung Cancer Medical Institute, Champions Oncology and ROS1ders Enter into Agreement 12
Addario Lung Cancer Medical Institute Enters into Agreement with Scancell 13
Addario Lung Cancer Medical Institute, Key Competitors 14
Addario Lung Cancer Medical Institute, Key Employees 15

List of Figures
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Addario Lung Cancer Medical Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Addario Lung Cancer Medical Institute, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Addario Lung Cancer Medical Institute:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Andhra Petrochemicals Ltd (500012)
    Andhra Petrochemicals Ltd (500012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Singapore Exchange Limited (S68):企業の財務・戦略的SWOT分析
    Singapore Exchange Limited (S68) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Astron Corporation Ltd (ATR):企業の財務・戦略的SWOT分析
    Astron Corporation Ltd (ATR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • AiCuris GmbH & Co KG-製薬・医療分野:企業M&A・提携分析
    Summary AiCuris GmbH & Co KG (AiCuris), a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company’s pipeline products include antiviral and antibacterial agents …
  • China Chemical & Pharmaceutical Co Ltd (1701):企業の財務・戦略的SWOT分析
    China Chemical & Pharmaceutical Co Ltd (1701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Allergy Therapeutics Plc (AGY):企業の財務・戦略的SWOT分析
    Allergy Therapeutics Plc (AGY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Flexion Therapeutics Inc (FLXN)-製薬・医療分野:企業M&A・提携分析
    Summary Flexion Therapeutics Inc (Flexion) is a pharmaceutical company that develops and commercializes pain therapies. The company's products comprise FX006, FX007, and FX005. Its FX005 is a p38 mitogen-activated protein, kinase inhibitor that contains both analgesic and anti-inflammatory propertie …
  • Dell Technologies Inc (DVMT):医療機器:M&Aディール及び事業提携情報
    Summary Dell Technologies, Inc. (Dell), is a provider of desktop personal computers, software and peripherals. The company designs, develops, manufactures, markets, sells and supports information technology infrastructure such as laptops, desktops, mobiles, workstations, storage devices and printers …
  • Shopping Centres Australasia Property Group RE Limited:企業の戦略・SWOT・財務情報
    Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report Summary Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Epigenomics AG (ECX):医療機器:M&Aディール及び事業提携情報
    Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi pro …
  • PT Tigaraksa Satria Tbk (TGKA):企業の財務・戦略的SWOT分析
    PT Tigaraksa Satria Tbk (TGKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Hybrigenics SA (ALHYG):企業の財務・戦略的SWOT分析
    Hybrigenics SA (ALHYG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Polpharma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Polpharma SA (Polpharma) undertakes the research, manufacture and marketing of generic drugs, prescription drugs and over the counter medications. It provides drugs in cardiology, gastroenterology and neurology areas. The company also manufactures over the counter (OTC) medications, dietary …
  • Zalando SE:企業の戦略・SWOT・財務分析
    Zalando SE - Strategy, SWOT and Corporate Finance Report Summary Zalando SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • G4S Plc (GFS):企業の財務・戦略的SWOT分析
    G4S Plc (GFS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Saudi Electricity Co (5110):電力:M&Aディール及び事業提携情報
    Summary Saudi Electricity Co (SEC) is an energy utility. Through its subsidiaries, the company generates, transmits and distributes electricity; and carries out operations of the fiber optic networks, trading, realization of renewable energy, and other. It produces electricity in gas, combined, stea …
  • Carnival Corporation & Plc (CCL):企業の財務・戦略的SWOT分析
    Carnival Corporation & Plc (CCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Gritstone Oncology Inc (GRTS):製薬・医療:M&Aディール及び事業提携情報
    Summary Gritstone Oncology Inc (Gritstone) develops and commercialize tumor-specific cancer immunotherapies. The company’s pipeline product portfolio comprises GRANITE-001, for solid tumors, including metastatic non-small cell lung cancer and gastroesophageal, bladder and colorectal cancers; and SLA …
  • Kylemore Services Group:企業の戦略・SWOT・財務分析
    Kylemore Services Group - Strategy, SWOT and Corporate Finance Report Summary Kylemore Services Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Asian Infrastructure Investment Bank:電力:M&Aディール及び事業提携情報
    Summary Asian Infrastructure Investment Bank (AIIB) is a multilateral financial institution. The company develops infrastructure and other productive sectors. It provides sovereign and non-sovereign finance for sustainable projects in energy and power, transportation and telecommunications, rural in …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆